Stockscreener 앱 받기
0.00
100.00%
-15.02
시간 외 거래:
14.90
14.90
+
Definium Therapeutics Inc 주식(MNMD)의 최신 뉴스
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - Sahm
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - Newswire Canada
Is Rising 2025 Loss and Investor Outreach Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
DFTX Should I Buy - Intellectia AI
Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising R&D Costs - GuruFocus
Decoding Definium Therapeutics Inc (DFTX): A Strategic SWOT Insi - GuruFocus
Definium Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Definium Therapeutics Q4 2025 reports strong R&D investment By Investing.com - Investing.com South Africa
Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Definium Therapeutics Issues Inducement Stock Options to New Hires - TipRanks
Definium Therapeutics Inc: Four pivotal phase III studies near completion, with strong cash reserves and key data readouts ahead - TradingView
Definium Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Definium Therapeutics posts full-year 2025 financial results, releases business update - Traders Union
Definium Therapeutics (DFTX) maps late-stage trials in anxiety, depression and autism - Stock Titan
[8-K] Definium Therapeutics, Inc. Reports Material Event | DFTX SEC FilingForm 8-K - Stock Titan
Definium Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga España
Definium Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Wolfe Research - Defense World
Earnings Preview For Definium Therapeutics - Benzinga
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Is It Too Late To Consider Definium Therapeutics (DFTX) After A 158% One Year Surge? - Sahm
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
DFTX: Wolfe Research Initiates Coverage with Outperform Rating | - GuruFocus
Definium Therapeutics to Participate at Upcoming Investor Conferences - The Globe and Mail
Definium Therapeutics (DFTX) to Release Quarterly Earnings on Thursday - MarketBeat
Jefferies assigns 65–75% probability of best-in-class efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - MSN
Avoro Capital Advisors LLC Acquires 5 Million Shares in Definium Therapeutics Inc - GuruFocus
CenterBook Partners LP Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - The Joplin Globe
Jefferies’ DT120 Confidence and Psychedelic Tailwinds Might Change The Case For Investing In Definium Therapeutics (DFTX) - Sahm
Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III - Bitget
Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - Insider Monkey
Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 8.3%Still a Buy? - MarketBeat
Should I buy Definium Therapeutics, Inc. (DFTX) - Zacks Investment Research
Commodore Capital reports 7.2% Definium Therapeutics (DFTX) ownership stake - Stock Titan
7 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Roger Adsett Joins The Board - Sahm
What is the current Price Target and Forecast for Definium Therapeutics, Inc. (DFTX) - Zacks Investment Research
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says - Law360
Definium Therapeutics Announces New Employee Inducement GrantsFebruary 3, 2026 - BioSpace
Definium Therapeutics stock hits 52-week high at 18.19 USD By Investing.com - Investing.com Nigeria
LSD therapy biotech Definium sued for alleged trade secret theft | Business Information & News | FE - Westlaw Today
LSD therapy biotech Definium sued for alleged trade secret theft - Reuters
Company Researching LSD Applications Faces Trade Secrets Litigation in Delaware Federal Court - Law.com
Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week HighShould You Buy? - MarketBeat
0.11%
6.00%
자본화:
|
볼륨(24시간):